Does Mounjaro become less effective the longer you take it?

The biggest misconception: a plateau means the medicine stopped working

When the scales stop moving as fast as they did in the first few weeks, many people conclude Mounjaro has lost its power. It almost certainly hasn't. What's happened is more straightforward: your body weighs less, burns fewer calories at rest, and has adapted its energy balance to a lower intake. The medicine is still doing exactly what it does, activating GIP and GLP-1 receptors, slowing gastric emptying, keeping appetite suppressed. The plateau is a physiology story, not a pharmacology failure.

This distinction matters practically. If you treat a normal plateau as evidence the medicine is broken, you might stop treatment prematurely or assume nothing can be done. The NHS tirzepatide medicines page is clear that tirzepatide works as part of a programme that includes diet and activity changes, the medicine supports those efforts; it does not replace them. When both are in place, continued effectiveness is the norm, not the exception.

The other thing worth naming: a true loss of response, where appetite suppression genuinely weakens over time, does occasionally occur. But it is far less common than a lifestyle-driven plateau, and it has a clinical path forward, dose review with your prescriber.

What the SURMOUNT-1 trial tells us about long-term results

SURMOUNT-1 followed thousands of adults with obesity over 72 weeks (nearly a year and a half) and the results did not show effectiveness collapsing over time. Participants at the 15mg maintenance dose achieved around 20–21% average body-weight reduction by the end of the trial, with weight loss continuing across the full study period rather than stopping at month three or four. That sustained trajectory is one reason NICE recommended tirzepatide in its appraisal published in December 2024.

The dose matters here. The starter dose of 2.5mg exists to let your system adjust, nausea risk drops sharply when you begin low and titrate slowly. Therapeutic effect builds as the dose increases, which is why most meaningful weight loss in trials was recorded at 10mg and above. If you are still on an early dose, the medicine is not yet working at its intended level. That is a timing question, not an effectiveness question.

One quick check you can do right now: look at which dose you are currently on and when your last increase was. If you have been at the same dose for more than eight weeks and feel your appetite suppression has faded, that is worth raising with your prescriber at your next review. It takes under a minute and gives the conversation a concrete starting point. You can also read more about when Mounjaro is most effective across the dose schedule.

Factors that genuinely reduce Mounjaro's effectiveness

There are things that do blunt the medicine's impact, and most of them are correctable. Inadequate protein intake leads to muscle loss alongside fat loss, which drops your metabolic rate and makes the plateau feel worse. Significantly underestimating calorie intake happens easily when appetite is suppressed, because people sometimes eat less than their body needs without realising it, then compensate in irregular bursts. Poor sleep consistently undermines GLP-1 therapy outcomes in real-world data. Alcohol adds calories and disrupts hunger hormones. None of these mean Mounjaro has stopped working; they mean the environment around it needs attention.

Practical guides on how to get more from Mounjaro cover the lifestyle levers in detail. For the cost side of continuing treatment, the Mounjaro pricing page sets out what private treatment realistically involves month to month.

Storage is also worth mentioning briefly. If you are using or considering a tirzepatide ampoule, the same refrigeration rules apply: tirzepatide must be kept between 2–8°C, and any ampoule left at room temperature for longer than the window specified in the Patient Information Leaflet may lose potency. If you have had any doubts about a pen's storage conditions, check the leaflet and contact your pharmacy before using it.

What to do if you genuinely think your dose is no longer enough

A clinical review is the right next step, not switching products independently, not stopping, and not ordering a higher dose without clinical sign-off. At nume, every repeat order is reviewed by a GPhC-registered prescriber before it is processed, and dose changes are assessed on clinical grounds each time. That review process exists precisely for moments like this: your prescriber can look at your weight trajectory, your current dose, how long you have been on it, and whether an increase or a different approach is appropriate.

If you are wondering whether tirzepatide is the right medicine for your situation at all, the broader tirzepatide overview and the effectiveness evidence page cover the clinical picture in full. And if you are weighing up whether to continue private treatment, our FAQs address common questions about the review process. A diminishing response is rarely the end of the story, it is usually the prompt for a conversation with your prescriber. Check your eligibility and start that conversation with our clinical team.